Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 9;192(10):4748–4757. doi: 10.4049/jimmunol.1303190

Figure 6. Inhibition of A2t prevents HPV16-induced immune suppression of LC.

Figure 6

A. Inhibition of A2t increases immunogenicity of HPV16 PsV. LC were left untreated (Unt.), or treated with LPS, HPV16 PsV, or treated with increasing concentrations of A2t inhibitor (A2ti) alone or A2ti prior to exposure to HPV16 PsV and subsequently analyzed via flow cytometry for the change in expression of MHC II and CD86. B. LC exposed to A2ti and HPV16 PsV show increased secretion of Th1-associated chemokines compared to LC treated with HPV16 PsV alone. LC were left untreated (Unt.) or treated with LPS, HPV16 PsV, A2ti (25 μM), or A2ti plus HPV16 PsV. Supernatants were collected at 48 hours and analyzed in triplicate for the presence of cytokines and chemokines. These data are a representative example of an experiment performed three times expressed as the mean concentration ± SD (**P < 0.01, ***P < 0.001 as determined by a two-tailed, unpaired t-test, as compared to HPV16 PsV only treated LC).